Adult Leukemia Program, Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.
Hematol Oncol Clin North Am. 2020 Apr;34(2):449-463. doi: 10.1016/j.hoc.2019.11.003. Epub 2020 Jan 7.
Secondary acute myeloid leukemia (sAML) is a complex diagnosis that includes AML caused by either an antecedent hematologic disease (AML-AHD) or from previous treatment with chemotherapy or radiation. This disease carries a poor prognosis and is historically chemorefractory; additionally, often patients are ineligible for standard chemotherapy because of advanced age and other comorbidities. The advances of molecular diagnostics and reclassification of World Health Organization criteria have aided in the categorization of this disease. This article describes the etiology and pathophysiology of sAML, and delves into past successful treatments as well as promising new treatments.
继发性急性髓系白血病(sAML)是一种复杂的诊断,包括由先前的血液疾病(AML-AHD)或先前的化疗或放疗引起的 AML。这种疾病预后不良,且在历史上对化疗有抵抗性;此外,由于年龄较大和其他合并症,通常患者不符合标准化疗的条件。分子诊断学的进步和世界卫生组织标准的重新分类有助于对这种疾病进行分类。本文描述了 sAML 的病因和病理生理学,并深入探讨了过去的成功治疗方法以及有前途的新治疗方法。